Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer

Blasco-Benito, Sandra, Moreno, Estefanía, Seijo-Vila, Marta, Tundidor, Isabel, Andradas, Clara, Caffarel, María M., Caro-Villalobos, Miriam, Urigüen, Leyre, Diez-Alarcia, Rebeca, Moreno-Bueno, Gema, Hernández, Lucía, Manso, Luis, Homar-Ruano, Patricia, McCormick, Peter J., Bibic, Lucka, Bernadó-Morales, Cristina, Arribas, Joaquín, Canals, Meritxell, Casadó, Vicent, Canela, Enric Isidre, Guzmán, Manuel, Pérez-Gómez, Eduardo and Sánchez, Cristina (2019) Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 116 (9). pp. 3863-3872. ISSN 1091-6490

[img]
Preview
PDF (PNAS-HER2) - Submitted Version
Available under License ["licenses_description_other" not defined].

Download (729kB) | Preview

Abstract

There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2–CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer.

Item Type: Article
Additional Information: Erratum at: 10.1073/pnas.1903209116
Faculty \ School: Faculty of Science > School of Pharmacy
Depositing User: LivePure Connector
Date Deposited: 08 Feb 2019 12:30
Last Modified: 20 Aug 2020 00:29
URI: https://ueaeprints.uea.ac.uk/id/eprint/69893
DOI: 10.1073/pnas.1815034116

Actions (login required)

View Item View Item